

PUBLICATIONS:

Papers

1. **Sarosdy MF**, Brock WA, Parsons LA: Scrotal actinomycosis. J Urol 121:256,1979.
2. **Sarosdy MF**, Lamm DL, Radwin HM, Von Hoff DD: Assay for clonogenic cells of human genitourinary cancer. Surgical Forum, XXXI: 583, 1980.
3. **Sarosdy MF**, Kledzik G, Lamm DL: Serum and bone marrow radioimmunoassay of acid phosphatase in prostatic cancer. Urology, XIX: 33, 1982.
4. **Sarosdy MF**, Lamm DL, Radwin HM, Von Hoff DD: Clonogenic assay and in vitro chemosensitivity testing of human urologic malignancies. Cancer 50:1332, 1982.
5. **Sarosdy MF**, Lamm DL: Application of mixed cell agglutination test for cell surface antigens to renal cell carcinoma. J Urol 128:693, 1982.
6. Lamm DL, **Sarosdy MF**: Chemosensitivity testing in urological cancer. Urology Update Series 1:14, 1982.
7. Suarez AJ, Lamm DL, Radwin HM, **Sarosdy MF**, Clark H, Osborne CK: Androgen priming and cytotoxic chemotherapy in advanced prostatic cancer. Cancer chemother Pharmacol 8:261, 1982.
8. Zeltzer PM, **Sarosdy MF**, Von Hoff DD, Schneider S, Seeger R, Schlesinger H: Preclinical chemosensitivity testing using human neuroblastoma cell lines in soft agar: A new tumor specific drug screening model. Clin Res 30:139A, 1982.
9. **Sarosdy MF**, Von Hoff DD: Prediction of response of cancer chemotherapy. Drugs 26:454, 1983.
10. Von Hoff DD, Clark GM, Stogdill BJ, **Sarosdy MF**, O'Brien MT, Casper JT, Mattox DE, Page CP, Cruz AB, Sandbach JF: Prospective clinical trial of a human tumor cloning system. Cancer Res 43:1926, 1983.
11. Saylor RP, Wright LF, **Sarosdy MF**, Banowsky LH: Hypercalcemia-induced upper gastrointestinal bleeding after renal transplantation. Urology 24:337, 1984.
12. **Sarosdy MF**, Saylor R, Dittman W, Cruz A, Banowsky L: Upper gastrointestinal bleeding following renal transplantation. Urology 26: 347, 1985.
13. **Sarosdy MF**, Zeltzer PM, Von Hoff DD, Schneider SL, Forseth BJ: In vitro chemosensitivity testing of human neuroblastoma cell lines in soft agar: A tumorspecific drug screening model. Invest New Drugs 4:135, 1986.
14. **Sarosdy MF**, Pickett SH, Stogdill BJ, Rochester MG, Reynolds R, Radwin HW, Lamm DL: Immunotherapy and immunodiagnostic studies in carcinoma of the bladder. World J Urol, 3: 215, 1986.
15. **Sarosdy MF**, Kierum C, Yager K, Neubauer BL: Use of a rapid colorimetric assay for in vitro chemosensitivity testing of urologic cancers and cell lines. Surgical Forum XXXVII:664, 1986.
16. **Sarosdy MF**, Rochester M, Yi-Peng F: A new technique for continent urinary diversion. J Urol 137:1020, 1987.

17. **Sarosdy MF**: Urethral cancer. Urology Update Series 6:13, 1987.
18. Swanson DA, Anthony WA, Avant OL, Curtis WP, Ferrell Jr JM, Keegan GT, McMillin Jr TR, Peters PC, **Sarosdy MF**, Warren MW, Zagars GK: Urologic Cancer. Oncology guidelines report. Texas Medicine 83(2): 17, 1987.
19. Rochester MG, **Sarosdy MF**, Stogdill BJ, Pickett SH, Lamm DL: Tumor-specific immunotherapy of murine bladder cancer with butanol-extracted antigens and ethylchlorformate polymerized tumor protein. J Urol 140: 647, 1988.
20. **Sarosdy MF**, Hudnall CH, Erickson DR, Hardin TC, Novicki DE: A prospective double-blind trial of intracorporeal papaverine versus prostaglandin E-1 in the treatment of impotence. J Urol 141:551, 1989.
21. **Sarosdy MF**, Lamm DL: Long term results of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol 142: 719, 1989.
22. **Sarosdy MF**, Einhorn LH, Donohue JP, Von Hoff DD: Correlation of clonogenic growth with histologic diagnosis after resection of residual tissue following chemotherapy for nonseminomatous testis cancer. Urology 34:396, 1989.
23. **Sarosdy MF**, Kierum CA: Combination immunotherapy of murine transitional cell carcinoma using BCG and an interferon-inducing pyrimidinone. J. Urol 142(5):1376, 1989.
24. **Sarosdy MF**: Do we have a rational treatment plan for stage D-1 carcinoma of the prostate? World J Urol 8:27, 1990.
25. Lamm DL, DeHaven JI, Shriver J, Crispin R, Grau D, **Sarosdy MF**: A randomized prospective comparison of oral versus intravesical and percutaneous BCG for superficial bladder cancer. J Urol 144:65, 1990.
26. Rawls WH, Lamm DL, Lowe BA, Crawford ED, **Sarosdy MF**, Montie JE, Grossman HB, Scardino PT: Fatal sepsis following intravesical BCG administration for bladder cancer: A Southwest Oncology Group Study. J Urol 144:1328, 1990.
27. Lamm DL, DeHaven JI, Shriver J, **Sarosdy MF**: Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer. J Urol 145:738, 1991.
28. Sharifi R, Lee M, Clayton M, Lamb D, Siami P, Strub M, Albert D, **Sarosdy MF**: Phase I - II evaluation of intravesical novantrone (mitoxantrone) in superficial bladder cancer. Anticancer Drugs 2:153, 1991.
29. Phillips TH, Ritchey ML, Dunn CD, **Sarosdy MF**: Complications of the Heitz-Boyer urinary diversion: Case report of late development of malignancy. J Urol 146:159, 1991.
30. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisc TH, Smith JA Jr, Sullivan J, **Sarosdy MF**, Crissman JD, Coltman CA: A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Eng J Med 325:1205, 1991.
31. **Sarosdy MF**, Lamm DL, Williams RD, Moon TD, Flanigan RC, Crawford ED, Wilks NE, Earhart RH, Merritt JA: Phase I trial of oral bropirimine in superficial bladder cancer. J Urol 147:31, 1992.

32. Neubauer BL, Merriman RL, Best KL, Goode RL, **Sarosdy MF**, Tanzer LR, Howbert JJ: Inhibition of PAIII rat prostatic adenocarcinoma growth and metastasis by a new diarylsulfonylurea antitumor agent, LY181984. *J Urol* 147:500, 1992.
33. Lippman HR, Ghiatas AA, **Sarosdy MF**: Systematic transrectal ultrasound guided prostate biopsy after negative digitally directed prostate biopsy. *J Urol* 147:827, 1992.
34. **Sarosdy MF**: High-dose versus low-dose intravesical interferon-*alpha*2b in the treatment of carcinoma *in situ*: a randomized, controlled study. *Anti-Cancer Drug Int'l J. Anti-Cancer Agents*, 3:Supp 1:13, 1992.
35. **Sarosdy MF**: Continent urinary diversion using cutaneous ileocecectomy. *Urology* 40:102, 1992.
36. Loehrer PJ, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, **Sarosdy MF**, Lowe BA, Blumenstein B, Trump D: A randomized comparison of cisplatin alone or in combination with methotrexate, vinorelbine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. *J Clin Oncol* 10(7): 1066-73, 1992.
37. Neubauer BL, Best KL, Goode RL, Heiman ML, Hoover DM, Robertson DW, **Sarosdy MF**, Shaar CJ, Tanzer LR, Merriman RL: Comparative Antitumor Effects of Hormonal Ablation, Estrogen Agonist, Estrogen Cytotoxic Derivative, and Antiestrogen in the PAIII Rat Prostatic Adenocarcinoma. *Cancer Res* 52(17): 4663, 1992.
38. Cookson MS, **Sarosdy MF**: Management of stage T1 superficial bladder cancer with intravesical BCG therapy. *J Urol* 148:797, 1992.
39. Bajorin DF, **Sarosdy MF**, Pfister DG, Mazumdar M, Motzer RJ, Scher HI, Geller NL, Fair WR, Herr H, Sogani P, Scheinfeld J, Russo P, Vlamos V, Carey R, Vogelzang NJ, Crawford ED, Bosl GJ: A randomized trial of etoposide & cisplatin versus etoposide & carboplatin in patients with good risk germ cell tumors. A multi-institutional study. *J Clin Oncol* 11(4): 598-606, 1993.
40. **Sarosdy MF**: Bopiramine in bladder cancer: Clinical studies. *Annals of the New York Academy of Sciences Immunomodulating Drugs* 685:301-308, 1993.
41. **Sarosdy MF**: Management of superficial bladder cancer: Adjuvant therapy. *Oncology Update* 10(3): 1-12, 1993.
42. **Sarosdy MF**, Hutzler DH, Yee D, Von Hoff DD: *In vitro* sensitivity testing of human bladder cancers and cell lines to TP-40: a hybrid protein with selective targeting and cytotoxicity. *J Urol* 150: 1950-1955, 1993.
43. Cookson MS, **Sarosdy MF**: Hormonal therapy of metastatic prostate cancer: Issues of timing and total androgen ablation. *Southern Medical Journal* 87:1-6, 1994.
44. Goldberg MR, Heimbrook DC, Russo P, **Sarosdy MF**, Greenberg RE, Giantonio RE, Linehan MJ, Fisher HAG, Messing E, Crawford ED, Oliff AI, Pastan IH: Phase I Clinical Study of the Recombinant Oncotoxin TP40 in Superficial Bladder Cancer. *Clinical Cancer Research* 1:57-61, 1995.
45. Van Den Berg C, Guan X-Y, Von Hoff D, Jenkins R, Bittner M, Griffin C, Kallonen O, Visakorpi T, McGill J, Heart J, Epstein J, Meltzer P, **Sarosdy MF**, Trent J: DNA sequence amplification in human prostate cancer identified by chromosome microdissection: potential prognostic implications. *Clinical Cancer Res* 1:11, 1995.

46. **Sarosdy MF**: Intravesical and oral therapy for the treatment and prophylaxis of Ta, TCIS and T1 bladder cancer. *Urology International* 2:12, 1995.
47. Schellhammer P, Sharifi R, Block N, Soloway MS, Venner P, Cox C, **Sarosdy MF**, Jones J, and Kolvenbag G: A controlled trial of bicalutamide (Casodex) versus flutamide (Eulexin), each in combination with luteinizing hormone releasing hormone analogue therapy, in patients with advanced prostate cancer. *Urology* 45: 745, 1995.
48. Terry PJ, Houser EE, Rivera FJ, Palmaz JC, **Sarosdy MF**: Percutaneous aortic stent placement for life-threatening aortic rupture due to metastatic germ cell tumor. *J Urol* 153:631, 1995.
49. Saidi MH, **Sarosdy MF**, Hollimon PW, Sadler RK: Intestinal obstruction and bilateral ureteral injuries after laparoscopic oophorectomy in a patient with severe endometriosis. *J Amer Assoc Gyn Laparoscopies* 2:355, 1995.
50. **Sarosdy MF**, deVere White RW, Soloway MS, Sheinfeld J, Hudson MA, Schellhammer PF, Jarowenko MV, Adams G, Blumenstein BA: Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. *J Urol* 154:379, 1995.
51. Cookson MS, Floyd MK, Ball TP, Miller EK and **Sarosdy MF**: The lack of predictive value of prostate specific antigen density in the detection of prostate cancer in patients with normal rectal exams and intermediate PSA's. *J Urol* 154:1070, 1995.
52. Lamm DL, Blumenstein BA, Crawford ED, Crissman JD, Lowe BA, Smith JA, **Sarosdy MF**, Schellhammer PF, Sagalowsky AI, Messing EM, Loehrer P, Grossman HB: Randomized intergroup comparison of Bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder. *Urologic Oncology* 1:119, 1995.
53. Cookson MS, **Sarosdy MF**: Treatment of intratubular germ cell neoplasia and low stage testis cancer. *Current Opinion in Urology* 5:255, 1995.
54. Neubauer BL, Best KL, Counts DF, Goode RL, Hoover DM, Jones CD, **Sarosdy MF**, Shaar CJ, Tanzer LR, Merriman RL: Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model. *The Prostate* 27:220, 1995.
55. King DHC, Centeno AS, Saldivar VA, **Sarosdy MF**: Renal cell carcinoma metastatic to the gallbladder or prostate: two case reports. *Urology* 46:722-725, 1995.
56. **Sarosdy MF**: Immunotherapy of Superficial Bladder Cancer. *AUA Update Series* 29:14, 1995.
57. **Sarosdy MF**: Controversies over the use of PSA in the screening and diagnosis of localized prostate cancer. *San Antonio Medicine* 48(12):10, 1995.
58. Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson L, **Sarosdy MF**, Vogelzang N, Jones J, Kolvenbag G: Maximum androgen blockade for patients with metastatic prostate cancer: Outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. *Urology* 47(Suppl 1A): 54-60, 1996.
59. King DHC, **Sarosdy MF**, Hlavinka TC: Additional experience with continent urinary diversion using cutaneous ileocecostoplasty. *Urology* 47: 471-475, 1996.
60. **Sarosdy MF**, Higdon AL, and DeMoor CA: In vivo antitumor activity of bropirimine against PAIII and Dunning Mat-LyLu rodent prostate cancers. *J Urol* 155:2085-2089, 1996.

61. **Sarosdy MF**, Lowe BA, Schellhammer PF, Lamm DL, Graham SD, Grossman HB, See WA, Peabody JO, Moon TD, Flanigan RC, Crawford ED, Morganroth J: Oral bropiramine immunotherapy of carcinoma in situ of the bladder: Results of a phase II trial. *Urology* 48:21-27, 1996.
62. **Sarosdy MF**, Pisters LL, Carroll PR, Benson MC, Moon TD, Lamm DL, Hudson MA, Koch MO, Schellhammer PF: Bopiramine immunotherapy of upper urinary tract carcinoma in situ. *Urology* 48:28-32, 1996.
63. Sakaguchi AY, Sedlak M, Harris JM, **Sarosdy MF**: Cautionary note on the use of dUMP-containing PCR primers with Pfu and Ventr DNA Polymerases. *BioTechniques* 21:368-370, 1996.
64. **Sarosdy MF**: Global Perspectives - Case Studies in Urology: Transitional Cell Carcinoma. Case Discussion. *Urology International* 3:5-7, 1996.
65. Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, **Sarosdy MF**, Vogelzang NJ, Chen Y, Kolvenbag GJCM: A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer: Analysis of time to progression. *Cancer* 78:2164-2169, 1996.
66. Soloway MS, Briggman JV, Carpinito GA, Chodak GW, Church PA, Lamm DL, Lange PH, Messing EM, Pasciak RM, Reservitz GB, Rukstalis DB, **Sarosdy MF**, Stadler WM, Thiel RP, Hayden CL: Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. *J Urol* 156: 363-367, 1996.
67. Carpinito GA, Stadler, WM, Briggman JV, Chodak GW, Church PA, Lamm DL, Lange PH, Messing EM, Pasciak RM, Reservitz GB, Ross RN, Rukstalis DB, **Sarosdy MF**, Soloway MS, Thiel RP, Vogelzang NJ, Hayden CL: Urinary nuclear matrix (NMP22™) as a marker for transitional cell carcinoma of the urinary tract. *J Urol* 156: 1280-1285, 1996.
68. Sakaguchi AY, Sedlak M, Rogenes V, Harris JM, **Sarosdy MF**: Determining exon-intron junctions using uncloned genomic walking libraries and direct P1 sequencing. *Genet. (Life Sci Adv)* 14 19-25, 1996.
70. Sharkey FE, **Sarosdy MF**: The significance of central pathology review in clinical studies of transitional cell carcinoma-in-situ. *J Urol* 157:68-71, 1997.
71. **Sarosdy MF**: Radical cystectomy or bladder preservation for clinically localized invasive bladder cancer? *AUA News - January/February 1997* (by invitation).
72. **Sarosdy MF**: Oral Bopiramine Immunotherapy of Rodent Prostate Cancer. *European Urol* 31:5-9, 1997.
73. **Sarosdy MF**: A Review of Clinical Studies of Bopiramine Immunotherapy of Carcinoma in Situ of the Bladder and Upper Urinary Tract. *European Urol* 31:20-26, 1997.
74. **Sarosdy MF**: The use of the BTA Test in the detection of persistent or recurrent TCC of the bladder. *World Journal of Urology* 15:103-106, 1997.
75. Xiao H, Mazumdar M, Bajorin DF, **Sarosdy MF**, Vlamis V, Spicer J, Ferrara J, Bosl GJ, Motzer RJ: Long-term Follow-up of Patients with Good-Risk Germ Cell Tumors Treated with Etoposide and Cisplatin. *Journal of Clinical Oncology* 15:2553-2558, 1997.
76. Schellhammer PF, Patterson AL, Sharifi R, **Sarosdy MF**, Block N, Vogelzang NJ, Soloway M, Schellenger J, Venner P, Kolvenbag GJCM: Clinical benefits of Bicalutamide (Casodex) versus

Flutamide (Eulexin) in combined androgen for patients with advanced prostatic carcinoma: Final report of a double-blind randomized, multicenter trial. *Urology* 50:330- 336, 1997.

77. **Sarosdy MF**, Hudson MA, Ellis WJ, Soloway MS, deVere White R, Sheinfeld J, MVJarowenko, Schellhammer PF, Schervish EW, Patel JV, Chodak GW, Lamm DL, Johnson RD, Henderson M, Adams G, Blumenstein BA, Thoelke KR, Brunelle SL, Pfalzgraf RD, and Murchison HA: Improved detection of recurrent bladder cancer using the Bard® BTA *stat*™ Test. *Urology* 50:349- 353, 1997.
78. Lackner JE, **Sarosdy MF**: Current Status of Intravesical Chemotherapy for Recurrent Carcinoma of the Bladder. *Mediguide to Urology*, October, 1997.
79. **Sarosdy MF**, Bailey M: *Fast Facts - Indispensable Guides to Clinical Practice: Bladder Cancer*. Health Press, Oxford, UK; 1998.
80. **Sarosdy MF**, Manyak MJ, Sagalowsky AI, Belldegrun A, Benson MC, Bihrlle W, Carroll PR, Ellis WJ, Hudson MA, and Sharkey FE: Oral Bropirimine Immunotherapy of Bladder Carcinoma in Situ After Prior Intravesical Bacillus Calmette Guerin. *Urology* 51:226-231, 1998.
81. **Sarosdy MF**: Management of the T1G3 Superficial Bladder Cancer: The Role of BCG. *AUA Update Series*, February, 1998.
82. **Sarosdy MF**, Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Vogelzang NJ, Chodak GW, Schellenger JJ, Kolvenbag GJCM: Comparison of Goserelin and Leuprolide in Combined Androgen Blockade for Patients with Advanced Prostate Cancer. *Urology* 52:82-88, 1998.
83. **Sarosdy MF**, Schellhammer PF, Soloway MS, Vogelzang NJ, Crawford ED, Presti J, Mitchell P, and Porter L: Endocrine effects, efficacy, and tolerability of a 10.8-mg depot formulation of Zoladex (goserelin acetate) administered every 13 weeks to patients with advanced prostate cancer. *The BJU International* 83:801-806, 1999.
84. McLeod DG, Schellhammer PF, Vogelzang NJ, Soloway, MS, Sharifi R, Block NL, Venner PM, Patterson AL, **Sarosdy MF**, Kelly PR, and Kolvenbag GJCM: Exploratory Analysis on the Effect of Race on Clinical Outcome in Patients with Advanced Prostate Cancer Receiving Bicalutamide or Flutamide, Each in Combination with LHRH Analogues. *The Prostate* 40:218-24, 1999.
85. Messing EM, Manola J, **Sarosdy MF**, Wilding G, Crawford ED, and Trump D: Immediate hormonal therapy versus observation in men with node positive prostate cancer following radical prostatectomy and pelvic lymphadenectomy: A randomized Phase III Eastern Cooperative Oncology Group/Intergroup Trial. *New England Journal of Medicine* 341:1781-1788, 1999.
86. Saric T, Brkanac Z, Troyer DA, Padalecki SS, **Sarosdy M**, Williams K, Abadesco L, Leach RJ, and O'Connell P: Genetic Pattern of Prostate Cancer Progression. *Inter Jour Cancer* 81:219-224, 1999.
87. **Sarosdy, MF**: Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate cancer: the transitions from a first- to second-generation antiandrogen. *Anticancer Drugs* 10:791-796, 1999.
88. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, **Sarosdy MF**, Bohl RD, Grossman HB, Beck TM, Leimert JT and Crawford ED: Maintenance BCG Immunotherapy in Recurrent TA, T1 and Carcinoma in Situ Transitional Cell Carcinoma: A Randomized Southwest Oncology Group Study. *J Urol.* 163:1124-1129, 2000.

89. **Sarosdy MF**, Schellhammer P, Johnson R, Carroll K, and Kolvenbag GJCM: Does prolonged combined androgen blockade have survival benefits over short term CAB therapy? *Urology* 55:391-396, 2000.
90. Prestidge BR, Bice WS, Walker ES, and **Sarosdy MF**: Spatial dose-mapping following transperineal permanent prostate brachytherapy. *Int. J. Radiat. Oncol. Biol. Phys.* 48(3):148, Jan, 2000.
91. Soloway MS, Schellhammer PF, Sharifi R, Block NL, Venner PM, Patterson AL, **Sarosdy MF**, Vogelzang NJ, Schellenger JJ, and Kolvenbag GJCM: Bicalutamide and Flutamide, each in combination with Leuteinizing Hormone-Releasing Hormone Analogs, in advanced prostate cancer: exploratory analysis of extent of disease by Bone Scan on outcome. *The Prostate Journal*, July 2000, Vol 2(3):137-145(9).
92. Arar N, Thompson I, **Sarosdy M**, Harris M, Shepherd D, Troyer D, Plaetke R: Risk perceptions among patients and their relatives regarding prostate cancer and its heredity. *Prostate Cancer Prostatic Dis.* 2000 Nov;3(3):176-185.
93. Bice WS, Prestidge BR, and **Sarosdy MF**: Calibration, calculation, and prescription issues in permanent prostate brachytherapy with (103)Pd. *Int J Radiat Oncol Biol Phys.* 2001 Jan 1;49(1):289-91.
94. Plaetke R, Thompson I, **Sarosdy M**, Harris JM, Troyer JD, and Arar NH: Genetic fieldwork for hereditary prostate cancer studies. *Urol Oncol* 7:19-27, 2002.
95. **Sarosdy MF**, Schellhammer P, Bokinsky G, Kahn P, Chao R, Yore L, Zadra J, Burzon D, Osher G, Bridge J, Anderson S, Johansson L, Lieber M, Soloway M, and Flom K: Clinical Evaluation of a Multi-target Fluorescent in-Situ Hybridization Assay for Detection of Bladder Cancer. *J Urol* 168:1950-1954, 2002.
96. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, **Sarosdy MF**, Wood DP, Raghavan D, and Crawford ED: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. *NEJM* 349:859-866, 2003.
97. Herr HW, Faulkner JR, Grossman HB, Natale RB, deVere White R, **Sarosdy MF**, Crawford ED: Surgical factors influence bladder cancer outcomes: a cooperative group report. *J Clin Oncol.* 2004 Jul 15;22(14):2781-9. Epub 2004 Jun 15.
98. **Sarosdy MF**: Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate carcinoma with or without external beam radiation therapy. *Cancer* 2004 Aug 15;101(4):754-60.
99. **Sarosdy MF**, Tangen CM, Weiss GR, Nestok BR, Benson MC, Schellhammer PF, Sagalowsky AI, Wood DP Jr, Crawford ED: A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guerin for carcinoma in situ of the bladder: a Southwest Oncology Group Study. *Urol Oncol* 2005 Nov-Dec;23(6):386-9.
100. **Sarosdy MF**, Kahn PR, Ziffer MD, Love WR, Barkin J, Abara EO, Jansz K, Bridge JA, Johansson SL, Persons DL, Gibson JS: Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. *J Urol* 2006 Jul; 176(1):44-7.
101. **Sarosdy MF**: Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. *Cancer* 2007 Feb 1;109(3):536-41.

102. Pastuszak AW, Khanna A, Badhiwala N, Morgentaler A, Hult M, Connors W. **Sarosdy MF**, Yang C, Carrion R, Lipshultz LI, Khera M: Testosterone Therapy after Radiation Therapy for Low, Intermediate and High Risk Prostate Cancer. *J Urol* 2015 Nov; 194:1271-1276.

Chapters

1. Lamm DL, **Sarosdy MF**, DeHaven JI: Percutaneous, oral, or intravesical BCG administration: What is the optimal route? in: BCG in Superficial Bladder Cancer. DeBruyne FMJ, Denis L, and van der Meijden APM (eds), New York, Alan R. Liss Inc. 1989.
2. Lamm DL, Crissman J, Blumenstein B, Crawford ED, Montie J, Scardino P, Grossman HB, Stanisc T, Smith J, Sullivan J, and **Sarosdy MF**: Adriamycin versus BCG in superficial bladder cancer: A Southwest Oncology Group Study. in: BCG in Superficial Bladder Cancer. DeBruyne FMJ, Denis L, and van der Meijden APM (eds), New York, Alan R. Liss Inc., 1989.
3. **Sarosdy MF**: Testicular cancer: An overview. in: Current Genitourinary Cancer Surgery. Crawford ED and Das S (eds), Philadelphia, Lea and Febiger, 1990.
4. **Sarosdy MF**: Management of the male urethra following cystectomy for invasive bladder carcinoma. in: The Urologic Clinics of North America. Crawford ED and Das S (eds), Philadelphia, WB Saunders, May, 1992.
5. **Sarosdy MF**: Principles of Intravesical Chemotherapy and Immunotherapy. in: "Superficial Bladder Cancer," The Urologic Clinics of North America. Lamm DL (ed), Philadelphia, WB Saunders, August, 1992.
6. **Sarosdy MF**: Genitourinary cancer. in: Clinical Oncology. Weiss G (ed), San Mateo, Appleton and Lange, 1993.
7. **Sarosdy MF**: Prostate cancer-pelvic confined. in: Clinical Urology. Krane R, Siroky M, and Fitzpatrick J (eds), Massachusetts, JB Lippincott Company, 1994.
8. **Sarosdy MF**: Immunotherapy of Bladder Carcinoma. In: Current Genitourinary Cancer Surgery, 2nd Edition. Crawford ED, Das S (ed), Philadelphia, Lea and Febiger, 1996.
9. Terry PJ, Cookson MS, **Sarosdy MF**: Carcinoma of the Urethra. in: Principles and Practice of Genitourinary Oncology. Raghavan D, Scher HI, Leibel SA, and Lange P (ed), Philadelphia, JB Lippincott, 1997.
10. Harris JM, **Sarosdy MF**: The Use of Biological Modifiers in the Treatment of Superficial Bladder Cancer. In: Superficial Bladder Cancer. Pagano F, Fair WR (ed), Oxford, ISIS Medical Media, 1997.
11. Terry PJ, **Sarosdy MF**: Urethral carcinoma in the male and female: Management and Prognosis. In: Urologic Oncology. Oesterling JE, Ritchie JP (ed), Philadelphia, W. B. Saunders Company, 1997.
12. Harris JM, **Sarosdy MF**: New diagnostic developments and the possibility of oral agents for the treatment of bladder cancer. In: Recent Advances in Urology 7. Kirby RS, O'Leary MP, Haddock GM, Affleck F (ed), Churchill Livingstone, Midlothian, UK, in press.

13. Harris JM, **Sarosdy MF**: Superficial bladder tumors: The place of adjuvant intravesical chemotherapy. In: Adjuvant Treatment in Urological Cancer. Abi-Aad AS (ed), Parthenon Publishing, in press.
14. **Sarosdy MF**: Intravesical Treatment of Superficial Transitional Cell Carcinoma. In: Urologic Malignancies. Hamdy F, Basler J, Neal D, Catalona W (eds), Churchill Livingstone, in press.
15. Freiha GS, **Sarosdy MF**: Topical Chemotherapy. In: Urologic Malignancies. Hamdy F, Basler J, Neal D, Catalona W (eds), Churchill Livingstone, in press.

Published Abstracts

1. Von Hoff DD, Clark GM, **Sarosdy MF**, Stogdill B, Sandbach J: Clinical correlations for a human tumor cloning system. Abstracts of Third EORTC-NCI New Drug Meeting, Brussels, Belgium, 1981.
2. **Sarosdy MF**, Lamm DL: Dianhydrogalactitol chemotherapy of murine transitional cell carcinoma. Abstracts of the 76th Annual Meeting of the American Urological Association, Boston, MA 1981, p. 117.
3. **Sarosdy MF**, Lamm DL, Radwin HM, Von Hoff DD: In vitro clonal assay and chemosensitivity testing of human urologic malignancies. Abstracts of the 76th Annual Meeting of the American Urological Association, Boston, MA 1981, p. 196.
4. **Sarosdy MF**, Lamm DL, Radwin HM, Von Hoff DD: In vitro chemosensitivity testing in human urologic cancers. Abstracts of the 78th Annual Meeting of the American Urological Association, Las Vegas, NV 1983, p. 114.
5. Neubauer BL, Best KL, Goode RL, Merriman RL, **Sarosdy MF**, Tanzer LR, Howbert JJ: Inhibition of PAIII rodent prostatic adenocarcinoma growth and metastasis by a new sulfonylurea antitumor agent. J Urol, 135(Suppl): 114A, 1986.
6. Lamm DL, Pilot S, **Sarosdy MF**: Oral BCG vs. intravesical plus percutaneous BCG in superficial transitional cell carcinoma. J. Urol., 135(Suppl): 186A, 1986.
7. Lamm DL, DeHaven JI, **Sarosdy MF**: Progress and controversies in BCG immunotherapy of superficial bladder cancer. Proceedings - International Workshop in Urology, Cannes, France, 1987, p. 219-222.
8. Williams R, **Sarosdy MF**, Catalona W, Chodak G, Vogelzang N, Freiha F, Torti F: Randomized trial of high vs. low dose intravesical interferon alpha 2-b (IFN-A2B) treatment of bladder carcinoma in situ (CIS). Proceedings - 24th Annual Meeting of the American Society of Clinical Oncology, March 1988, p. 121.
9. Rockwood AP, Jennings AW, Clark GM, McGuire WL, **Sarosdy MF**: Prediction of failure of BCG immunotherapy in superficial bladder cancer by flow cytometric analysis of pre-therapy archival bladder tumors. J Urol, 139(Suppl):371A, 1988.
10. **Sarosdy MF**, Grau DG, Lamm DL: Long-term results of bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol, 139(Suppl):229A, 1988.

11. Hudnall CH, Erickson DR, **Sarosdy MF**: Evaluation of intracorporeal prostaglandin E-1 in the treatment of impotence--A pilot study. *J Urol*, 139(Suppl):252A, 1988.
12. Lamm DL, **Sarosdy MF**, Grau DG, Buchanan J, Hunt J, DeHaven J: Randomized prospective comparison of intravesical Tice BCG immunotherapy with and without percutaneous administration. *J Urol*, 139(Suppl):300A, 1988.
13. **Sarosdy MF**, Kierum CA, Munoz DA: Potentiation of bacillus Calmette-Guerin activity in murine bladder cancer by the pyrimidinone interferon inducer ABPP. *J Urol*, 139(Suppl):300A, 1988.
14. Lamm DL, Crissman J, Crawford ED, Blumenstein B, Montie JE, Scardino PT, Grossman HB, Stanisc T, Smith JA, **Sarosdy MF**: BCG versus adriamycin intravesical therapy for in situ and papillary transitional cell carcinoma of the urinary bladder: A Southwest Oncology Group Study. Proceedings - 25th Annual Meeting of American Society of Clinical Oncology, May 21-23, 1989.
15. Neubauer BL, Best KL, Goode RL, Jones CD, Merriman RL, **Sarosdy MF**, Shaar CL, Tanzer LR, Hirsch KS: Anti-tumor effects of LY117018 in the PAIII rat prostatic adenocarcinoma. *J Urol*, 141(Suppl):501A, 1989.
16. Peretsman SJ, **Sarosdy MF**: Combination immunotherapy of murine transitional cell carcinoma with methylprednisolone and bacillus Calmette-Guerin. *J Urol*, 141 (Suppl):232A, 1989.
17. Freiha F, Shortliffe L, Palmer J, Meyers F, Spaulding (NCOG) J, Williams R, **Sarosdy MF**, Catalona W, Chodak G, Vogelzang N, Torti F: Alpha interferon for carcinoma in situ of the bladder. Proceedings - New Trends in Urology, The Netherlands, September 13-16, 1989.
18. Lamm DL, **Sarosdy MF**, Grossman HB, Bohl RD, Hatch T, Moon TD, Crawford ED, Lowe BA, Weems WL, Blumenstein B, Crissman J, Beck TM, Montie J, Smith JA: Maintenance vs. nonmaintenance BCG immunotherapy of superficial bladder cancer: A Southwest Oncology Group Study. *J Urol*, 143(Suppl):341A, 1990.
19. **Sarosdy MF**, Lamm DL, Williams RD, Moon TD, Flanigan RC, Crawford ED, Merritt JE: Phase I trial of oral bropirimine (ABPP) in superficial bladder cancer. *J Urol*, 143(Suppl):256A, 1990.
20. Lippman HR, **Sarosdy MF**: Transrectal ultrasound guided prostate biopsy after negative digitally directed prostate biopsy. *J Urol*, 143(Suppl):365A, 1990.
21. Merritt J, Lamm D, Williams R, Moon T, Flanigan R, Crawford E, **Sarosdy MF**: Phase I/II trial of oral bropirimine (BROP) in superficial bladder cancer. Program/Proceedings American Society of Clinical Oncology - 26th Annual Meeting, May 20-22, 1990.
22. Von Hoff DD, Hutzler DH, **Sarosdy MF**: Presence of extrachromosomal DNA in the form of double minutes in bladder cancer cell lines. *J Urol*, 145(Suppl): 333A, 1991.
23. Phillips DL, **Sarosdy MF**: The diagnostic benefit and complication rates of loop-o-grams to assess the upper tracts of patients after ileal conduit urinary diversion. *J Urol*, 145(Suppl):368A, 1991.
24. Bajorin DF, **Sarosdy MF**, Bosl GJ, Weisen S, Heller G, Investigators of Memorial Sloan-Kettering Cancer Center, Southwest Oncology Group & participating centers: A randomized trial of etoposide + carboplatin (EC) vs. etoposide + cisplatin (EP) in patients with metastatic germ cell tumors (GCT). Proceedings - 27th Annual Meeting of the American Society of Clinical Oncology 10:168, 1991.
25. **Sarosdy MF**, Cookson MS: Management of stage T1 tumors with BCG. *J Urol*, 147:273A, 1992.

26. Lamm DL, Crawford ED, Blumenstein B, Crissman JD, Montie J, Gottesman J, Lowe B, **Sarosdy MF**, Bohl RD, Weems WL, Grossman HB, Smith JA, Beck TM, Leimart J, Coltman CA: Maintenance BCG Immunotherapy of Superficial Bladder Cancer: A randomized Prospective Southwest Oncology Group Study. *J Urol*, 147:274A, 1992.
27. **Sarosdy MF**, Hutzler D, Von Hoff D: TP-40 in bladder cancer: A hybrid protein with selective targeting and cytotoxicity. *J Urol* 147:261A, 1992.
28. McGill J, Beitzel B, Norris L, Neilsen J, Hutzler D, **Sarosdy MF**, Von Hoff D: Double minute chromosomes are frequently found in tumors taken directly from patients. *Cancer Research* 33:40, 1992.
29. Bajorin DF, **Sarosdy MF**, Bosl GJ, Majumdar M and investigators of Memorial Sloan-Kettering Cancer Center, the Southwest Oncology Group and participating centers. Memorial Sloan-Kettering Cancer Center, NY, NY 10021: Good risk germ cell tumor (GCT): A randomized trial of etoposide + carboplatin (EC) vs. Etoposide + cisplatin (EP). *J Clin Onc* 11:203, 1992.
30. Lamm DL, Crawford ED, Blumenstein B, Crissman JD, Montie J, Gottesman J, Lowe B, **Sarosdy MF**, Bohl RD, Weems WL, Grossman HB, Smith JA, Beck TM, Leimert J, Coltman CA: Maintenance BCG Immunotherapy of Superficial Bladder Cancer: A randomized prospective Southwest Oncology Group Study. *J Clin Onc* 11:627, 1992.
31. **Sarosdy, MF**: TP-40 in Bladder Cancer: A Hybrid Protein with Selective Targeting and Cytotoxicity. 2nd Annual Symposium on Cancer Research in San Antonio, pp.15, July 24, 1992.
32. **Sarosdy, MF**: Intravesical chemotherapy and immunotherapy of superficial bladder cancer. Chemotherapy Foundation Symposium on "Innovative Cancer Chemotherapy For Tomorrow," in *Cancer Investigation* Vol. 11(Suppl):10, 1992.
33. Lamm DL, Crawford ED, Blumenstein B, Crissman J, de Vere White R, Wolf M, Lowe B, **Sarosdy MF**, Schellhammer P, Sagalowsky A, Smith J, Grossman HB, Flanigan R, Moon T, Brendler C, Coltman C: SWOG 8795: A randomized comparison of Bacillus Calmette-Guerin and mitomycin C prophylaxis in stage Ta and T1 transitional cell carcinoma of the bladder, *J Urol* 149:282A, 1993
34. Griffin KP, Segura L, Kan N, Cooper MJ, **Sarosdy MF**: The effects on proliferation, metabolism and tumorigenicity of MBT-2 using a retroviral vector human wild type p53 gene. *J Urol* 149:485A, 1993.
35. Griffin K, Segura L, Cooper MJ, **Sarosdy MF**: The effects on proliferation, metabolism and tumorigenicity of MBT-2 using a retroviral vector with human wild type p53 gene. *Cancer Research* 34:538, 1993.
36. **Sarosdy MF**: Clinical studies of broprimine in superficial bladder cancer. Chemotherapy Foundation Symposium on "Innovative Cancer Chemotherapy For Tomorrow," in *Cancer Investigation* Vol. 12(Suppl): 25, 1993.
37. **Sarosdy MF**, Lowe BA, Schellhammer PF, Lamm DL, Graham, Jr. SD, Grossman HB, See WA, Peabody JO, Moon TD, Flanigan RC, Crawford ED, Earhart RH: Broprimine Immunotherapy of Bladder CIS: Positive Phase II Results of an Oral Interferon Inducer. *J Clin Onc* 13:233, 1994
38. deVere White RW, Deitch AD, Gandour-Edwards R, Blumenstein B, Lowe B, **Sarosdy MF**, Schellhammer P: DNA Ploidy is Highly Predictive of Disease Progression in Patients with Transitional Cell Carcinoma (TCC) Receiving Intravesical Chemotherapy. *J Urol* 151:231A, 1994.

39. **Sarosdy MF**, Lowe BA, Schellhammer PF, Lamm DL, Graham SD, Grossman HB, See WA, Peabody JO, Moon TD, Flanigan RC, Crawford ED, and Earhart RH: Bropiramine Immunotherapy of Bladder CIS: Positive Phase II Results of an Oral Interferon Inducer. *J Urol* 13:304A, 1994.
40. Cookson MS, Floyd MK, Miller EK, Ball TP, and **Sarosdy MF**: Detection of Prostate Cancer in Patients with Normal DRE's and PSA's of 4.0-10.0 ng/mL Independent of PSAD. *J Urol* 13:450A, 1994.
41. Vogelzang NJ, Schellhammer PF, Block NL, Soloway MS, Venner PM, Patterson AL, **Sarosdy MF**, Jones JA and Kennealey GT: A randomized double-blind trial in 813 previously untreated metastatic prostate cancer (CaP) patients (PTS) comparing a new antiandrogen Casodex (Bicalutamide) with Eulexin (Flutamide) in combination with luteinizing hormone releasing hormone analogue (LHRH-a) therapy. *J Clin Oncol* 14:242, 1995.
42. Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, **Sarosdy MF**, Jones J, and Kolvenbag G: Casodex in combination therapy: A comparison with flutamide in patients with untreated metastatic prostate cancer. *J Urol* 153:449A, 1995.
43. **Sarosdy MF**, deVere-White R, Soloway MS, Sheinfeld J, Hudson MA, Ellis WJ, Messing EM, Johnson RD, Patel JV, Schervish EW, Chodak GW, Lamm DL, Henderson M, and Blumenstein BA: Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. *J Urol* 153:232A, 1995.
44. **Sarosdy MF** and Higdon A: Bropiramine immunotherapy prevents implantation and induces regression of existing PAIII prostate cancer. *J Urol* 153:270A, 1995.
45. Terry PJ, Craig FE, Higdon AL, Sharkey FE and **Sarosdy MF**: Effects of bropiramine immunotherapy on bladder cancer induced by N-Butyl-N-(4-Hydroxybutyl) Nitrosamine (BBN) using a rat model. *J Urol* 153:524A, 1995.
46. Briggman J, Soloway MS, Messing E, Carpinito G, Rukstalis D, Church P, Pasciak R, **Sarosdy MF**, Chodak G, Hayden C, and Thiel R: A tumor marker to detect occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. *European Society of Clinical Pathology*, Vienna, Austria, May 24, 1995.
47. Venner P, Schellhammer P, Block N, Soloway M, Patterson AL, **Sarosdy MF**, Jones J, and Kolvenbag G: Casodex in combination with luteinizing hormone releasing hormone (LHRH) analogue therapy: A comparison with flutamide in combination with LHRH analogue therapy for patients with previously untreated metastatic prostate cancer. *Canadian Urological Association Annual Meeting*, 1996 (in press).
48. Nichols CR, Loehrer PJ, Einhorn LH, Propert K, Vogelzang NJ, Crawford ED, **Sarosdy MF**, Trump D: Phase III study of Cisplatin, Etoposide and Bleomycin (PVP16B) or Etoposide, Ifosfamide and Cisplatin (VIP) in advanced stage germ cell tumors; an intergroup trial. *J Clin Oncol* 14:239, 1995.
49. Schellhammer PF, Vogelzang NJ, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, **Sarosdy MF**, Jones JA, Kennealey GT, Kolvenbag GJCM: Updated results of a randomized, double-blind trial in 813 previously untreated metastatic prostate cancer (CaP) patients (PTS) comparing the antiandrogens Casodex (Bicalutamide) and Eulexin (Flutamide) in combination with luteinizing hormone releasing hormone analogue (LHRH-A). *J Clin Oncol* 15:245, 1996.
50. Kennealey GT, Vogelzang NJ, Soloway MS, Schellhammer PF, Sharifi R, Block N, Venner P, Patterson L, **Sarosdy MF**, Jones J, Kolvenbag GJCM: Analysis of time to treatment failure by extent of disease and race in a randomized, multicenter trial comparing Casodex (Bicalutamide) (C) with

Eulexin (Flutamide) (E), each combined with luteinizing hormone releasing hormone analogue (LHRH-A) therapy. *J Clin Oncol* 15:251, 1996.

51. Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, **Sarosdy MF**, Vogelzang N, Jones J, and Kolvenbag G: Analysis by extent of disease and race comparing Bicalutamide (Casodex) with Flutamide (Eulexin), each in combination with luteinizing hormone releasing hormone analogue (LHRH-A) therapy, in 813 patients (PTS) with advanced prostate cancer. *J Urol* 155:609A, 1996.
52. **Sarosdy MF**, Pisters LL, Carroll PR, Benson MC, Moon TD, Lamm DL, Hudson MA, Lerner SP, Koch MO, Graham SD, Schellhammer PF: Bopiramine is active against upper tract cytology positive for transitional cell cancer (TCC). *J Urol* 155:493A, 1996.
53. Ishak LM, Enfield DL, **Sarosdy MF**, and the multicenter group: Detection of recurrent bladder cancer using a new quantitative assay for bladder tumor antigen. *J Urol* 157:337A, 1997.
54. **Sarosdy MF**, Hudson MA, Ellis WJ, Soloway MS, deVere White RW, Sheinfeld J, Jarowenko MV, Schellhammer PF, Messing EM, Schervish EW, Patel JV, Chodak GW, Lamm DL, Johnson RD, Henderson M, Adams G, Blumenstein BA, Thielke KR, Brunelle SL, Pfalzgraf RD, Murchison HA. Detection of recurrent bladder cancer using a new one-step test for bladder tumor antigen. *J Urol* 157:337A, 1997.
55. Lamm DL, Blumenstein B, **Sarosdy MF**, Grossman HB, Crawford ED: Significant long-term patient benefit with BCG maintenance therapy: A Southwest Oncology Group study. *J Urol* 157:213A, 1997.
56. Xiao H, Mazumdar M, Bajorin DF, Bosl GJ, **Sarosdy MF**, Vlamis V, Spicer J, Farrara J, Motzer RJ: Long-term follow-up of patients with good-risk germ cell tumors treated with Etoposide and Cisplatin (EP). *Proceedings of American Society of Clinical Oncology*, 16:321a, 1997.
57. Smalley S, Lew D, Thompson I, **Sarosdy M**, Stephens R, Noble M, Kimler B: Protracted venous infusion (PVI) 5-FU and radiation as definitive therapy for stage C prostate cancer. *Proceedings of American Society of Clinical Oncology*, 16:343a, 1997.
58. **Sarosdy MF**, Faubion CL: Increased detection of bladder cancer recurrence by the Bard® BTA® test in patients with prior BTA test positive tumors. *South Central Section of the AUA Annual Meeting*, Bermuda, November 8-12, 1997.
59. **Sarosdy MF**, Faubion CL, and the multicenter study group. Increased detection of bladder cancer recurrence by the Bard BTA Test in patients with prior BTA Test positive tumors. *Societe Internationale d'Urologie*, Montreal, September 7-11, 1997. *British J Urol* (in press)
60. **Sarosdy MF**, Hudson MA, Ellis WJ, Soloway MS, deVere White RW, Sheinfeld J, Jarowenko MV, Schellhammer PF, Messing EM, Schervish EW, Patel JV, Chodak GW, Lamm DL, Johnson RD, Henderson M: Detection of recurrent bladder cancer using a new one-step test for bladder tumor antigen. *Societe Internationale d'Urologie*, Montreal, September 7-11, 1997. *British J Urol* (in press)
61. McGill J, Mattern V, Mangold G, **Sarosdy MF**, Izbicka E, Von Hoff D, Cerna C, Gomez L, Troyer D: Model to study stage-specific genetic changes in prostate cancer. *7th Annual Symposium on Cancer Research in San Antonio*, July 25, 1997.
62. Sakaguchi AY, Young A, Mattern V, McGill JR, Harris JM, **Sarosdy MF**, Patel P, Giambenardi TA, Klebe RJ, Chavez M. Genetic Organization of Telomere Binding Protein Genes. *7th Annual Symposium on Cancer Research in San Antonio*, July 25, 1997.

63. **Sarosdy MF**, Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Vogelzang NJ, Chodak GW, Schellenger JJ, Kolvenbag GJCM: Comparison of Four Combined Androgen Blockade Regimens for Stage D-2 Prostate Cancer. *J. Clin Oncol* 17:313, 1998.
64. Soloway MS, Schellhammer PF, Sharifi R, Block NL, Venner PM, Patterson AL, **Sarosdy MF**, Vogelzang NJ, Schellenger JJ, and Kolvenbag GJCM: Bicalutamide plus Leuteinizing Hormone-Releasing Hormone Analogue versus Flutamide plus LHRH-A in Patients with Stage D2 Prostate Cancer: Clinical Outcome by Extent of Disease Assessed by Bone Scan. *J. Clin Oncol* 17:313, 1998.
65. **Sarosdy MF**, Schellhammer PF, Block NL, Soloway MS, Venner PM, Patterson AL, Sharifi R, Vogelzang NJ, Chodak GW, Klein, EA, Schellenger JJ, and Kolvenbag GJCM: Comparison of Goserelin and Leuprolide in Combined Androgen Blockade for Advanced Prostate Cancer. *J.Urol* 159: 338, 1998.
66. Arar NH, **Sarosdy MF**, Thompson I, Harris M, Troyer D, Hernandez L, Garcia J, Hunt L, and Plaetke R: Beliefs and attitudes towards hereditary prostate cancer. *American Journal of Human Genetics*, October, 1998.
67. **Sarosdy MF**, Schellhammer PF, Soloway MS, Volgezang NJ, Crawford ED, Presti J, Mitchell P, and Porter L: 10.8 mg Goserelin acetate (Zoladex) every 13 weeks for advanced prostate cancer. *Annals of Oncology* 9(4): 58, 1998.
68. Kosecka U, Lamm D, **Sarosdy M**, and Wittes R: Intravesical BCG may protect against adenocarcinoma of the prostate. International Congress of Immunology, New Delhi India, November 1-6, 1998.
69. Messing E, Wilding G, **Sarosdy M**, Kiernan M, Crawford D, and Manoloa J: Immediate hormonal therapy versus observation for node positive prostate cancer following radical prostatectomy and pelvic lymphadenectomy: a randomized Phase III Eastern Cooperative Oncology Group/Intergroup Trial. *J. Urol.* 161: 175, 1999.
70. Lamm DL, Crissman JD, Montie JE, Gottesman JB, Lowe BA, **Sarosdy MF**, Bohl RD, Grossman HB, Beck TM, Leinert JT, Crawford ED, Kosecka U, and Wittes RC: Maintenance BCG immunotherapy: evidence of additional protection against cancer. A Southwest Oncology Group Study. *J. Urol.* 161: 285, 1999.
71. Prestidge BR, Bice WS, Walker ES, and **Sarosdy MF**: Spatial dose-mapping following transperineal interstitial permanent prostate brachytherapy. ASTRO annual meeting, October, 2000.
72. **Sarosdy MF**, Bice WS, and Prestidge BR: Prior transurethral resection (TUR) of the prostate reduces postoperative urinary morbidity associated with transperineal interstitial permanent prostate brachytherapy (PB). *I.J.Radiation Oncology.Biology.Physics* 51(3) Supplement 1: 315,2001.
73. **Sarosdy M**, Schellhammer P, Kahn P, Yore L, Zadra J, Bridge J, Anderson S, Johansson S and Flom K: Clinical evaluation of a multi-target fluorescent in-situ hybridization assay for bladder cancer detection. *J. Urol* 165(5), Supplement:162, 2001.
74. Plaetke R, Thompson I, **Sarosdy M**, Harris JM, Troyer D, Arar NH: Genetic fieldwork for hereditary prostate cancer studies. *Uro Oncol* 2002 Jan-Feb;7(1):19-27.
75. **Sarosdy MF**, Machtens S: Advanced Bladder Cancer...Where are we now and where are we going? *World J Urol* 2002 Aug;20(3):143.

76. Takahashi T, Lohse C, Pankratz S, Karnes J, Flom K, **Sarosdy M**, Jenkins R, Lieber M, Zincke H, Blute M, and Halling K: Predicting Urothelial Carcinoma Recurrence with Fluorescence in Situ Hybridization Analysis of Urine. *J. Urol.* 167(4) Supplement: 162, 2002.
77. Messing E, Manola J, **Sarosdy M**, Wilding G, Crawford ED, and Trump D: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer: results at years of EST 3886. *J Urol* 169:396, 2003.
78. **Sarosdy, MF**: Urinary and rectal complications of contemporary prostate brachytherapy (PB) for prostate cancer (PC). *J Urol.* 169:491-2, 2003.
77. Messing E, Manola J, **Sarosdy M**, Wilding G, Crawford D, Kiernan M, Trump D: Immediate hormonal therapy versus observation after radical prostatectomy and pelvic lymphadenectomy for node positive prostate cancer: at 10 years results of EST3886. *ASCO Proceedings* 23:398, 2004.
78. **Sarosdy M**, Kahn P, Ziffer M, Love W, Abara E, Barkin J: Evaluation of a multi-target fluorescent in situ hybridization (FISH) assay in the initial diagnosis of bladder cancer in patients with hematuria. *J Urol* 171(4) Supplement:66, 2004.
79. **Sarosdy M**, Wilkerson M, Uhler M: Pulmonary seed migration after permanent transperineal prostate brachytherapy is relatively common. *J Urol* 171(4) Supplement:282, 2004.
80. Dziubinski JM, **Sarosdy MF**, Kahn PR, Ziffer MD, Love WR, Zadra JA, Schellhammer PF, Bokinsy GB, Stenzel TT: Multiple fluorescence in situ hybridization (FISH) probes increase sensitivity for detection of bladder cancer. *J Urol* 175(4):287-8, 2006.
81. **Sarosdy MF**: Testosterone replacement after brachytherapy for prostate cancer. *J Urol* 175(4):366, 2006.
82. **Sarosdy MF**: High disease-free survival 5-10 years after prostate brachytherapy associated with negative prostatic biopsies among failures. *J Urol* 177(4):189, 2007.

EDITORIAL COMMENT:

1. **Sarosdy MF**: Re: Messing E: Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with screening versus those with standard clinical presentations. *Urology* 45:396, 1995
2. **Sarosdy MF**: Re: Lamm DL: BCG Immunotherapy for Transitional-Cell Carcinoma in Situ of the Bladder. *Oncology* 9:961, 1995
3. **Sarosdy MF**: Re: D'Hallewin M, Baert L: Initial evaluation of the BTA Test in superficial bladder cancer. *J Urol* 155:475, 1996
4. Schellhammer PF, Soloway MS, Vogelzang NJ, **Sarosdy MF**, Jones JA, Kolvenbag GJCM: A Randomized, Comparative Trial of Casodex versus Flutamide Used in Combination with Medical Castration in Patients with Untreated Metastatic Prostate Cancer. *Urology* 48:661, 1996
5. **Sarosdy MF**: Re: Deantoni E: Age-Specific Reference Ranges for PSA in the Diagnosis of Prostate Cancer. *Oncology* 11:485-486, 1997
6. **Sarosdy MF**: Data Interpretation and Integration of New Tests Into Clinical Practice. *J Urol* 158:2107-2108, 1997

7. Schellhammer P, Block N, Sharifi R, Soloway M, Patterson L, Vogelzang N, **Sarosdy MF**, Furr B, Caplan R, Kolvenbag G: Reply to Letter of Labrie F, Sinard J, Singh S, and Candas B: Estimated potency of Casodes: A problematic design. *Urology* 50:311-313, 1997.

BOOK REVIEWS:

1. **Sarosdy MF**: Book Review: Goldenberg, SL: *The Intelligent Patient Guide to Prostate Cancer: All You Need to Know to Take an Active Part in Your Treatment*. Vancouver, Intelligent Patient Guide Ltd, 1992, 168 pp. *J Urol*, 150:1582, 1993

PRESENTATIONS (Peer Reviewed):

1. "Clonogenic assay and in vitro chemosensitivity testing in carcinoma of the kidney, ureter, bladder, prostate and testicle." American Urological Association-South Central Section, Kansas City, MO, October 14, 1980
2. "Serum and bone marrow radioimmune assay of acid phosphatase in prostatic cancer and benign prostatic hypertrophy." American Urological Association-South Central Section - Resident's Essay Contest, Kansas City, MO, October 14, 1980
3. "Assay for clonogenic cells of human genitourinary cancer." 66th Annual Clinical Congress of the American College of Surgeons, Atlanta, GA, October 22, 1980
4. "Dianhydrogalactitol chemotherapy of murine transitional cell carcinoma." 76th Annual Meeting of the American Urological Association, Boston, MA, May 10, 1981
5. "In vitro clonal assay and chemosensitivity testing of human urologic malignancies." 76th Annual Meeting of the American Urological Association, Boston, MA, May 13, 1981
6. "Application of mixed cell agglutination test for cell surface antigens to renal cell carcinoma." American Urological Association-South Central Section, Dallas, TX, September 14, 1981
7. "In vitro chemosensitivity testing in bladder cancer." American Urological Association-South Central Section, New Orleans, LA, September 13, 1982
8. "Upper gastrointestinal bleeding following renal transplantation." American College of Surgeons-South Texas Chapter, San Antonio, TX, January 17, 1983
9. "In vitro chemosensitivity testing in human urologic malignancies." 78th Annual Meeting of the American Urological Association, Las Vegas, NV, April 18, 1983
10. "The clonogenic assay: A urologic perspective." American Urological Association-North Central Section, Cedar Rapids, IA, September 22, 1984
11. "A new form of continent urinary diversion." American Urological Association-South Central Section, San Antonio, TX, October 2, 1986
12. "Use of a rapid colorimetric assay for in vitro chemosensitivity testing of urological cancers and cell lines. 72nd Annual Clinical Congress of the American College of Surgeons, New Orleans, LA, October 22, 1986
13. "Evaluation of intracorporeal prostaglandin E-1 in the treatment of impotence - A pilot study." 83rd Annual Meeting of the American Urological Association, Boston, May, June 6, 1988

14. "Long-term results of BCG immunotherapy for superficial bladder cancer." 83rd Annual Meeting of the American Urological Association, Boston, MA, June 6, 1988
15. "Potentiation of bacillus Calmette-Guerin activity in murine bladder cancer by the pyrimidinone interferon inducer ABPP." 83rd Annual Meeting of the American Urological Association, Boston, MA, June 6, 1988
16. "Randomized, prospective comparison of intravesical Tice BCG immunotherapy with and without percutaneous inoculation." 83rd Annual Meeting of the American Urological Association, Boston, MA, June 6, 1988
17. "Phase I trial of oral bropirimine (ABPP) in superficial bladder cancer." 85th Annual Meeting of the American Urological Association, New Orleans, LA, May 13, 1990
18. "Presence of extrachromosomal deoxyribonucleic acid in the form of double minutes in bladder cancer cell lines." 86th Annual Meeting of the American Urological Association, Toronto, Canada, June 2, 1991
19. "Urologic Investigations of the Southwest Oncology Group." Cancer Clinical Investigations: The San Antonio Experience, San Antonio, TX, October 7, 1991
20. "Timing of Androgen Ablation." 70th Annual South Central Section of the American Urological Association, Maui, Hawaii, November 17, 1991
21. "TP-40 in Bladder Cancer" A Hybrid Protein with Selective Targeting and Cytotoxicity." 87th Annual Meeting of the American Urological Association, Washington, DC, May 10-14, 1992
22. "Management of Stage T1 Tumors with BCG." 87th Annual Meeting of the American Urological Association, Washington, DC, May 10-14, 1992
23. "TP-40 in Bladder Cancer: A Hybrid Protein with Selective Targeting and Cytotoxicity." 2nd Annual Symposium on Cancer Research in San Antonio, San Antonio, TX, July 24, 1992
24. "Oral Bropirimine Immunotherapy for CIS of the Bladder." South Central Section of the American Urological Association Annual Scientific Convention, Acapulco, Mexico, October 4, 1993
25. "Bropirimine Immunotherapy of Bladder CIS: Positive Phase II Results of an Oral Interferon Inducer", American Urological Association Annual Meeting, San Francisco, California, May 16, 1994
26. "Bropirimine Immunotherapy of Bladder CIS: Positive Phase II Results of an Oral Interferon Inducer", American Society of Clinical Oncology Annual Meeting, Dallas, Texas, May 17, 1994
27. "Results of a Multicenter Trial Using the BTA® Test to Monitor for and Diagnose Recurrent Bladder Cancer", American Urological Association Annual Meeting, Las Vegas, Nevada, April 24, 1995
28. "Bropirimine Immunotherapy Prevents Implantation and Induces Regression of Existing PAILI Prostate Cancer", American Urological Association Annual Meeting, Las Vegas, Nevada, April 24, 1995
29. "Bropirimine is Active Against Upper Tract Cytology Positive for Transitional Cell Cancer (TCC)", American Urological Association Annual Meeting, Orlando, Florida, May 6, 1996
30. "Bladder and Germ Cell Tumors", American Society of Clinical Oncology Annual Meeting, Philadelphia, PA, May 21, 1996

31. "Management of the Patient with Systemic (M+) Disease: Current Data on Long-term Hormone Therapy", Prostate Cancer and Urology Business Practice: A Zeneca National Consultancy Workshop, St. Petersburg, FL, March 20-23, 1997
32. "Detection of recurrent bladder cancer using a new one-step test for bladder tumor antigen", American Urological Association Meeting, New Orleans, LA, April 15, 1997
33. "Increased detection of bladder cancer recurrence by the Bard BTA Test in patients with prior BTA Test positive tumors", Societe Internationale d'Urologie, Montreal, September 11, 1997
34. "Detection of recurrent bladder cancer using a new one-step test for bladder tumor antigen", Societe Internationale d'Urologie, Montreal, September 11, 1997
35. "Comparison of Goserelin and Leuprolide in combined androgen blockade (CAB) for advanced prostate cancer." American Urological Association Annual Meeting, San Diego, CA, June 3, 1998
36. "10.8 mg Goserilin every 13 weeks for Advanced Prostate Cancer." Joint Meeting of the British Oncological Association, Association of Cancer Physicians, and Royal College of Radiologists, Nottingham, England, July 6, 1998
37. "10.8 mg Goserelin acetate (Zoladex) every 13 weeks for advanced prostate cancer." Presented at the 23rd Congress of the European Society for Medical Oncology, Athens, Greece, November 8, 1998.
38. "Clinical evaluation of a multi-target fluorescent in-situ hybridization assay for bladder cancer detection." Annual Meeting of the American Urological Association, Anaheim, CA, June 2, 2001.
39. "Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate cancer with or without external beam therapy." Annual Meeting of the American Urological Association, Chicago, IL, April 30, 2003.
40. "Multiple fluorescence in situ hybridization (FISH) probes increase sensitivity for detection of bladder cancer." Annual Meeting of the American Urological Association, San Antonio, TX, May, 2005.
41. "Testosterone replacement after brachytherapy for prostate cancer." Annual Meeting of the American Brachytherapy Society, Philadelphia, PA, May, 2006.
42. "Testosterone replacement after brachytherapy for prostate cancer." Annual Meeting of the American Urological Association, Atlanta, GA, May, 2006.
43. "High disease-free survival 5-10 years after prostate brachytherapy associated with negative prostatic biopsies among failures." Annual Meeting of the American Urological Association, Anaheim, CA, May, 2007.